. Author manuscript; available in PMC: 2020 May 28.

Published in final edited form as: J Control Release. 2019 Apr 8;302:181–189. doi: 10.1016/j.jconrel.2019.04.009

Table 2. Inhibition of complement activation by clinically approved nanomedicines with SCR-2-3-4 in plasma of different healthy donors.

Each nanoparticle type was tested in 3 different plasma donors.

Particle	C3 IC₅₀, nM	C5a IC₅₀, nM	C3 at 4.1 µM (% of control)	C3 at 25 mM EDTA (% of control)
Feraheme	64.3	48.6	0.0	0.0
	72.9	366.9	0.1	0.0
	357.1	101.7	18.4	0.9
LipoDox	399.6	377.1	0.9	0.0
	343.4	385.8	2.5	0.0
	446.9	385.8	11.5	2.0
Onivyde	239.6	95.0	0.5	0.0
	90.2	96.7	3.3	0.0
	282.7	127.7	1.1	0.0